2021
How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCare
2006
Role of the molecular staging and response in the management of follicular lymphoma patients
Arcaini L, Colombo N, Bernasconi P, Calatroni S, Passamonti F, Orlandi E, Bonfichi M, Burcheri S, Della Porta M, Rumi E, Montanari F, Algarotti A, Pascutto C, Lazzarino M. Role of the molecular staging and response in the management of follicular lymphoma patients. Leukemia & Lymphoma 2006, 47: 1018-1022. PMID: 16840191, DOI: 10.1080/10428190500467834.Peer-Reviewed Original ResearchConceptsBcl-2/IgH rearrangementBcl-2 rearrangementBcl-2-negative patientsBcl-2 positive patientsPeripheral bloodMedian EFSMolecular respondersBone marrowNegative patientsPositive patientsClinical featuresBetter EFSIgH rearrangementsMedian event-free survivalBcl-2 negative casesEvent-free survivalFirst-line therapyCohort of patientsFollicular lymphoma patientsBcl-2Onset of diseaseMolecular responseBcl-2-positive casesInitial stagingLymphoma patients